TrialScope, a clinical trial transparency and compliance solutions provider, announced the availability of Convert, a free online clinical trial data conversion service.
TrialScope, a clinical trial transparency and compliance solutions provider, announced the availability of Convert, a free online clinical trial data conversion service. The complimentary service enables users to reuse clinical trial results data that was previously reported to the U.S. registry (clinicaltrials.gov) and convert it to the appropriate format for submission to the European registry (EudraCT).
Sponsors reporting results in Europe will need to have eligible clinical trials that ended between July 21, 2013 and July 21, 2014, to post results by July 21, 2015. Sponsors can gain access to the free conversion service from the TrialScope website at convert.trialscope.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.